Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominanceArticle Published on 2022-12-012023-07-10 Journal: Pharmacological Reports [Category] COVID19(2023년), [키워드] COVID-19 molnupiravir omicron Real-world experience SARS-CoV-2 Treatment [DOI] 10.1007/s43440-022-00408-6 PMC 바로가기
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceArticle Published on 2022-12-012023-07-10 Journal: Antiviral Research [Category] COVID19(2023년), [키워드] combination therapy in vivo molnupiravir Nirmatrelvir Remdesivir SARS-CoV-2 [DOI] 10.1016/j.antiviral.2022.105430 PMC 바로가기
COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patientsArticle Published on 2022-12-012022-11-15 Journal: Annals of Medicine [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] addition affecting alleviate antiviral medication antiviral medicine approved Baricitinib Care caused Clinical practice clinical recommendations Community courses COVID-19 COVID-19 pandemic COVID-19 patient COVID-19 treatment COVID-19 treatments Critical deaths develop disease disorder drug Dyspnea effective effective drugs European European Medicines Agency European Union Evidence guidelines Health healthcare hospital Hospitalization Hospitalized hospitalized patient hypoxia Intervention involved life-threatening lung involvement management Mild moderate molnupiravir monoclonal antibodies monoclonal antibody Most patient Multiorgan dysfunction New outcome public health recommendation Remdesivir Respiratory failure rheumatoid arthritis SARS-CoV-2 Septic shock severe symptom Symptom the disease the patient therapy Thromboembolism Tocilizumab treat Treatment treatment strategy union vaccination [DOI] 10.1080/07853890.2022.2133162 PMC 바로가기
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)Review Published on 2022-12-012023-07-11 Journal: Expert opinion on drug discovery [Category] COVID19(2023년), [키워드] ?-D-N4-hydroxycytidine COVID-19 molnupiravir oral therapy. RNA polymerase SARS-CoV-2 [DOI] 10.1080/17460441.2022.2153828 [Article Type] Review
Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Bioprocess and biosystems engineering [Category] SARS, 치료기술, [키워드] ACE acute respiratory syndrome angiotensin-converting enzyme 2 Angiotensin-converting enzyme 2 (ACE2) Asymptomatic binding caused combating contributed coronavirus coronavirus disease COVID-19 enzyme high affinity host receptor hydrophobic Infection Interaction lead to fatality Like molnupiravir Mutation Nanotechnology omicron pandemic pathogenic viruses PAXLOVID™ provide quercetin Remdesivir responsible SARS-CoV-2 spike glycoprotein suggested Transmissibility understanding Vaccine Vaccines viability virus [DOI] 10.1007/s00449-022-02788-8 PMC 바로가기
Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability – United States, December 23, 2021-August 28, 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] Analysis Antiviral collected COVID-19 COVID-19 therapeutics Critical death Department Dispensing distribution drug Emergency use authorization EUA FDA food higher risk highlight Hospitalization Human indicated Intervention medication medium Mild Moderate COVID-19 molnupiravir oral Patient Paxlovid provide recipient reduce risk service United States vulnerability [DOI] 10.15585/mmwr.mm7143a3 PMC 바로가기
Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 – United States, January-July 2022Article Published on 2022-10-282022-11-15 Journal: Morbidity and Mortality Weekly Report [Category] 치료제, [키워드] African American Alaska Antiviral Antiviral treatment antivirals Asian black booster doses Care COVID-19 COVID-19 in patient COVID-19 patient COVID-19 treatments COVID-19 vaccination disparity drug EHR Emergency use authorization EUA facilitate food Health help high risk highest Hispanic patient Immunocompromised less mAb medication Mild-to-moderate molnupiravir monoclonal antibody Native outcomes Outpatient Patient patient groups patients Paxlovid PROTECT Racial Remdesivir report risk seeking severe COVID-19 treated Treatment United States were used White patients [DOI] 10.15585/mmwr.mm7143a2 PMC 바로가기
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2Article Published on 2022-10-262023-07-10 Journal: Microbiology Spectrum [Category] COVID19(2023년), [키워드] Antiviral Calu-3 camostat Combination coronavirus DAA directly acting antiviral drug combinations Ebola host-targeting antiviral HTA molnupiravir Paxlovid SARS-CoV-2 synergy variant(s) of concern. [DOI] 10.1128/spectrum.03331-22 PMC 바로가기
Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of MechanismsReview Published on 2022-10-212023-07-10 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), [키워드] COVID-19 hepatitis C molnupiravir nucleoside analog RdRP Remdesivir RNA virus SARS-CoV-2 sofosbuvir Transcription [DOI] 10.3390/ijms232012649 PMC 바로가기 [Article Type] Review
Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant RecipientsArticle Published on 2022-10-092022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 치료제, [키워드] Acute kidney injury antiviral activity automated Comorbidity concerning cough COVID-19 COVID-19 therapy demonstrated diagnosed with COVID-19 dose Efficacy ESKD ESRD Fever Hemodialysis Immunosuppressive medication in vitro Interaction joint kidney Kidney disease kidney transplant kidney transplant recipient kidney transplant recipients Kidney transplantation knowledge molnupiravir Nasopharyngeal swab specimens nucleic acid amplification Observational cohort study Outpatient Pain Patient performed Poland positive-sense recipient resolved retrospective RNA viruses SARS-CoV-2 SARS-COV-2 infection serum creatinine Side effect therapy Transplant Treatment weakness [DOI] 10.3390/v14102224 PMC 바로가기